title: Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment.
authors.affiliation: DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University. kimd@sun.ac.za
authors.forename: K G P
authors.initials: KG
authors.lastname: Hoek
authors.forename: H S
authors.initials: HS
authors.lastname: Schaaf
authors.forename: N C
authors.initials: NC
authors.lastname: Gey van Pittius
authors.forename: P D
authors.initials: PD
authors.lastname: van Helden
authors.forename: R M
authors.initials: RM
authors.lastname: Warren
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage*; D023801:Directly Observed Therapy / Q000592:standards; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage*; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008826:Microbial Sensitivity Tests; D011718:Pyrazinamide / Q000008:administration & dosage*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol